Laxmi Organic Industries Limited
Laxmi Organic Industries Limited was established in 1989 and is in the business of specialty chemicals. The Company primarily manufactures Ethyl Acetate, Acetic Acid and Diketene Derivative Products (DDP). DDP is a specialty chemical group, the technology and business of which has been acquired by the company from Clariant Chemicals India Limited.The company‚Äôs business operations are carried in over 30 countries…
What Laxmi files
- Others76
- Investor Meet36
- Important34
- Board Meeting11
- PPTs9
- Updates7
Laxmi Organic delivered a strong Q1FY27, with revenue jumping 40% YoY to ₹968.3 crore. Profit After Tax (PAT) surged 216% to ₹67.7 crore, and EBITDA increased 272% to ₹114.3 crore. This robust performance was driven by volume and price growth across its portfolio. The Essentials segment saw 50% revenue growth...
Laxmi Organic's Q4FY26 revenue rose 4% YoY to INR 735.3 Cr, boosted by better price realizations. However, full-year FY26 revenue declined 5% to INR 2,846.7 Cr, with PAT dropping 30% to INR 79.4 Cr due partly to one-time factors. The Essentials segment was flat, but Specialties revenue fell 18% in...
Laxmi Organic reported Q3FY26 consolidated revenue of 718.7 Cr, down 9% year-on-year, with PAT at 25.4 Cr, a 13% decline. For 9MFY26, revenue stood at 2,111.4 Cr (down 7%) and PAT at 57.8 Cr (down 37%). Specialties segment revenue fell 30% in Q3 due to market price moderation and product...
Laxmi Organic Industries faced a tough Q2FY26 as consolidated revenue dipped 9% YoY to ₹699.7 Cr and PAT plunged 61% YoY to ₹11 Cr. H1FY26 saw revenues down 6% YoY to ₹1392.7 Cr and PAT down 48% YoY to ₹32.4 Cr. This decline stemmed from subdued ethyl acetate spreads and...
**1. Financial Highlights:** Q1FY26 revenue: **692.9 Cr** (-4% YoY); volumes grew 8%. PAT: **21.4 Cr** (-38%); Adj. EBITDA: **38.7 Cr** (-46%). Margins contracted from soft prices and a Specialties product phase-out. Essentials revenue rose 4%, Specialties declined 18%. **2. Strategic Initiatives & Growth Drivers:** Targets ~2x revenue, ~2.7x EBITDA, 20%...